Focus Session 2: ISSCR Industry Committee
Dr. George Smith leads portfolio and program management and oversees service delivery at the IQVIA Stem Cell Center, an organization he founded. He is an expert at strategy, translational medicine, pharmacology, due diligence, operations, organizational design and business development for drug discovery, contract research organizations and start-ups. He is experienced with drug development from concept through Phase III for a wide variety of therapeutic areas and therapeutic modalities. He has spent 20 years in the Biopharmaceutical industry at Pfizer, Althea Technologies, IQVIA Advisory Services and the Stem Cell Center. He also has a background in Venture and Angel investing and building start-up companies. George received his PhD from UCSD and the Salk Institute and his MBA from the Rady School of Business at UCSD.
09:05 – 09:25
Fate Therapeutics, Inc, United States
Bob Valamehr is the Vice President of Cancer Immunotherapy at Fate Therapeutics, overseeing the company’s immuno-oncology and pluripotent stem cell programs, including efforts to develop novel pluripotent cell strategies to create “off-the-shelf” cell-based cancer immunotherapeutics. Previously, Dr. Valamehr has played key scientific roles at Amgen, the Center for Cell Control (a NIH Nanomedicine Development Center) and the Broad Stem Cell Research Center developing novel methods to control pluripotency, to modulate stem cell fate including hematopoiesis and to better understand cellular signaling pathways associated with cancer. He has co-authored numerous studies and patents related to stem cell biology, oncology and materials science. Dr. Valamehr received his Ph.D. from the Department of Molecular and Medical Pharmacology at UCLA and his M.B.A. from Pepperdine University.
09:25 – 09:40
University College London, United Kingdom
Professor Pete Coffey, DPhil, is Head of Development, Ageing and Disease at UCLs Institute of Ophthalmology and the Co-Executive Director of Translation at UC Santa Barbara’s Center for Stem Cell Biology and Engineering. He is the principal author and co-author of two landmark papers demonstrating the use of human cells to halt visual deterioration in models of age-related macular degeneration. His achievements include the launch of the London Project to Cure Blindness, which aims to develop a stem cell therapy for the majority of all types of age-related macular degeneration, seminal work on retinal transplantation (as described by Debrossy & Dunnett, Nature Neuroscience 2001).
09:40 – 09:55
13:20 – 13:45
Dominic Wall has been directly involved in cell therapy manufacturing since the 1990's and is currently the Chief Scientific Officer of Cell Therapies Pty Ltd. He is also the Operations Director of the cell therapy services at the Peter MacCallum Cancer Centre. After completing his undergraduate education in London he completed a PhD at the University of Melbourne and became a fellow of the Faculty of Science (FFSc) from the Royal College of Pathologists of Australasia in 2010. He has administered various TGA cGMP licences on behalf of commercial sponsors working in immunotherapy and regenerative medicine, in the meantime having withstood 20 TGA inspections. His team is currently involved in commercial process development, and manufacturing with needle to needle control, as well as novel research in in-vivo cell therapy imaging using PET/SPECT and MRI, as well as supporting complex cell therapy trials such as Chimeric Antigen Receptor T cell immunotherapy. He is the current chair of the Legal & Regulatory Subcommittee of the International Society for Cell Therapy (ANZ).
10:10 – 10:30
Kim is passionate about empowering innovative technologies to disrupt current norms and accelerate commercial progress for emerging markets, particularly regenerative medicine. With over twenty years of commercial expertise, she has collaborated with diverse teams from the discovery bench to manufacturing suites, while coordinating efforts with corporate executive vision.
Kim has recently joined Akron Biotech where she will focus on improving the COGs for necessary ancillary materials such as cytokines to enable cGMP quality at even the earliest stages. Formerly the Director of Regenerative Medicine at Sartorius Stedim Biotech, she led the repurposing and refinement of their existing technologies, having partnered with clients at TAP Biosystems in both biologics and drug discovery to automation, cGMP, process robustness and comparability.
Previous positions advocating novel technology products at Invitrogen (now Thermo Fisher Scientific), Molecular Devices and Alltech (now W.R. Grace), have further equipped her with a broad knowledge of the life science marketplace. Kim earned a Bachelors degree in Chemistry from Northwestern University.
10:40 – 10:50
Lund University, Sweden
Malin Parmar is a professor in cellular neuroscience at Lund University. Together with her lab she has shown in a series of high profile publications how human fibroblasts can be converted into neurons, how glial cells can be reprogrammed into neurons in vivo, and how functional dopamine neurons can be generated from human embryonic stem cells. She is the recipient of an ERC starting grant and an ERC Consolidator grant as well as a VR Consolidator Grant. In 2016 she was awarded a New York Stem Cell Foundation – Robertson investigator award.
Her research has a strong translational focus and she collaborates with Industry partners to develop new, stem cell based therapies for Parkinson’s Disease.
Akitsu Hotta is Junior Associate Professor in the Center for iPS cell Research and Application (CiRA) at Kyoto University, and also Principle Investigator of the T-CiRA program, which is a joint research program between CiRA and Takeda Pharmaceutical company. In 2006, Dr. Hotta obtained his Ph.D. at Nagoya University for generating transgenic chicken by retroviral vectors to produce therapeutic antibodies in their eggs. Then, he moved to Dr. James Ellis’ lab at Hospital for Sick Children in Toronto as postdoctoral research fellow to study epigenetic regulation of retrovirus and retrotransposon in mouse and human embryonic stem cells. He was fascinated by the invention of iPS cell by Dr. Shinya Yamanaka and developed a lentivirus-based pluripotency reporter system to facilitate isolation of rare reprogrammed iPS cells. In 2010, he started his own laboratory at CiRA, focusing on utilizing iPS cells and genetic engineering tools, such as transposon vectors and genome editing platforms, to develop novel gene therapy for congenital disorders such as hemophilia and muscular dystrophies.
Cellular Dynamics International (CDI), WI, United States
14:30 – 14:45
The asset you are trying to access is locked. Please enter your access key to unlock.